MOONLAKE IMMUNOTHERAPEUTICS Cash and Restricted Cash
MOONLAKE IMMUNOTHERAPEUTICS (MLTX) had Cash and Restricted Cash of $477.90 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-10
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $477.90M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $298.49M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $334.52M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $350.74M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $477.90M 10-Q · filed 2026-08-10 | |
| 2026-03-31 | $298.49M 10-Q · filed 2026-05-11 | |
| 2025-12-31 | $334.52M 10-Q · filed 2026-08-10 | |
| 2025-09-30 | $350.74M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $306.68M 10-Q · filed 2026-08-10 | |
| 2025-03-31 | $271.57M 10-Q · filed 2026-05-11 | |
| 2024-12-31 | $180.43M 10-Q · filed 2026-08-10 | $180.43M 10-K · filed 2025-02-26 |
| 2024-09-30 | $375.65M 10-Q · filed 2025-11-05 | $375.66M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $342.79M 10-Q · filed 2025-08-05 | $342.79M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $458.44M 10-Q · filed 2025-05-12 | $458.44M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $451.17M 10-K · filed 2026-02-25 | $451.17M 10-K · filed 2024-02-29 |
| 2023-09-30 | $318.17M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $501.79M 10-Q · filed 2024-08-07 | |
| 2023-03-31 | $50.13M 10-Q · filed 2024-05-07 | |
| 2022-12-31 | $39.51M 10-K · filed 2026-02-25 | $39.51M 10-K · filed 2023-03-20 |
| 2022-09-30 | $41.20M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $92.71M 10-Q · filed 2023-08-10 | |
| 2022-03-31 | $8.83M 10-Q · filed 2023-05-11 | $101.00M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $8.04M 10-K · filed 2025-02-26 | |
| 2021-09-30 | $507.56K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $2.04M 10-Q · filed 2022-08-12 | |
| 2021-03-09 | $0.00 10-K · filed 2023-03-20 | |
| 2020-12-31 | $0.00 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |